8.20.19 | Maternal Health
Searching for Solutions to the Maternal Health Crisis
Maternal mortality rates in the United States are higher than anywhere else in the developed world, and the majority of the estimated 700 pregnancy-related deaths each year are preventable.
8.8.19 | Maternal Health
Examining Factors in the Maternal Health Crisis
The United States is the most dangerous country in the developed world to give birth, with an estimated 700 women dying from pregnancy-related deaths each year and 50,000 women experiencing life-threatening complications.
7.11.19 | Research and Clinical Trials
SWHR Submits Comments to FDA on Pregnancy and Lactation Draft Guidance
SWHR submitted comments to the FDA in response to draft guidance on considerations for pregnancy safety and lactation studies.
7.8.19 | Migraine
SWHR Creates Migraine Toolkit to Help Patients to Manage Their Care
SWHR's Migraine Patient Toolkit provides useful information about migraine diagnosis and treatment options, as well as tips on interacting with health care providers and health insurance companies to achieve the best possible outcomes.
7.8.19
Uterine Fibroids: Raising Awareness for an Overlooked Disease
Women with heavy menstrual bleeding, chronic pelvic pain, and similar symptoms are often unaware that these experiences are not normal.
7.2.19 | Policy
Improving Patient Outcomes: A Look at PCORI’s Research on Women’s Health
When patients and health care providers are forced to make health care decisions without sufficient evidence to inform them, the negative effects can be far-reaching.
6.14.19
SWHR Hires Lucy Erickson as Director of Scientific Programs
SWHR hired of Dr. Lucy Erickson as its new director of scientific programs. Erickson will design and lead innovative programs to increase awareness of and investment in women’s health and sex differences research.
6.11.19
Can Women’s Health Follow Personalized Medicine’s Path to Success?
Let me tell you a short story about a discovery in women that improved an entire field of treatment.
5.20.19 | Policy
Determining the Value of New Therapies: ICER Explores the Role of Real-World Evidence
Women won’t benefit from new therapies unless they can access them, and patient access to new innovations is based, in part, on value assessment.
